CD44 +/CD24 -/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

Human Pathology

Volumn 43, Issue 3, 2012, Pages 364-373

  Idowu, Michael O ^a   Kmieciak, MacIej ^b   Dumur, Catherine ^a   Burton, Regina S ^c   Grimes, Margaret M ^a   Powers, Celeste N ^a   Manjili, Masoud H ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Pathology Laboratory (APMC)   (United States)

Author keywords

Breast cancer; Recurrence; Stem cell phenotype; Triple negative

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; METASTASIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PROGNOSIS; TRANSGENIC MOUSE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 84857063740     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.05.005     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts and figures Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113. pdf. Atlanta, GA.
2. C.V. Ichim, and R.A. Wells First among equals: the cancer cell hierarchy Leuk Lymphoma 47 2006 2017 2027 (Pubitemid 44650076)
3. L.M. Merlo, J.W. Pepper, B.J. Reid, and C.C. Maley Cancer as an evolutionary and ecological process Nat Rev Cancer 6 2006 924 935 (Pubitemid 44862677)
4. L.L. Campbell, and K. Polyak Breast tumor heterogeneity: cancer stem cells or clonal evolution Cell Cycle 6 2007 2332 2338 (Pubitemid 350058682)
5. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111 (Pubitemid 33041634)
6. L.L. Song, and L. Miele Cancer stem cells-an old idea that's new again: implications for the diagnosis and treatment of breast cancer Expert Opin Biol Ther 7 2007 431 438 (Pubitemid 46524670)
7. M. Smalley, and A. Ashworth Stem cells and breast cancer. A field in transit Nat Rev Cancer 3 2003 832 844 (Pubitemid 37376981)
8. J. Russo, R. Moral, G.A. Balogh, D. Mailo, and I.H. Russo The protective role of pregnancy in breast cancer Breast Cancer Res 7 2005 131 142 (Pubitemid 40704134)
9. J. Cairns Mutation selection and the natural history of cancer Nature 255 1975 197 200
10. M. Al-Hajj, M.S. Wicha, and A. Benito-Hernadez Prospective identification of tumorigenic breast cancer cells Proc Natl Acd Sci U S A 100 2003 3983 3988 (Pubitemid 36418143)
11. M. Al-Hajj, M.W. Becker, and M. Wicha Therapeutic implications of cancer stem cells Curr Opin Genet Dev 14 2004 43 47 (Pubitemid 38167476)
12. C.I. Dumur, S. Nasim, and A.M. Best Evaluation of quality-control criteria for microarray gene expression analysis Clin Chem 50 2004 1994 2002 (Pubitemid 39425835)
13. M. Sugita, M. Geraci, and B. Gao Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma Cancer Res 62 2002 3971 3979 (Pubitemid 34791062)
14. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR the 2(-Delta Delta C(T)) method Methods 25 2001 402 408 (Pubitemid 34164012)
15. C.T. Guy, M.A. Webster, and M. Schaller Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci U S A 89 1992 10578 10582
16. M. Kmieciak, J.K. Morales, and J. Morales Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design Cancer Immunol Immunother 57 2008 1391 1398
17. M. Kmieciak, K.L. Knutson, C.I. Dumur, and M.H. Manjili HER-2/neu. antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses Eur J Immunol 37 2007 675 685 (Pubitemid 46916934)
18. R.A. Irizarry, B.M. Bolstad, and F. Collin Summaries of Affymetrix GeneChip probe level data Nucleic Acids Res 31 2003 e15
19. J.D. Storey A direct approach to false discovery rates J R Stat Soc B 64 2002 479
20. A. Giatromanolaki, E. Sivridis, A. Fiska, and M.I. Koukourakis The CD44+/CD24- phenotype relates to triple negative state and unfavorable prognosis in breast cancer patients Med Oncol 2010 [Epub ahead of print]
21. A. Worschech, M. Kmieciak, and K.L. Knutson Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors Cancer Res 68 2008 2436 2446 (Pubitemid 351521819)
22. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
23. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of HER2/neu protooncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
24. C.S. O'Brien, S.J. Howell, G. Farnie, and R.B. Clarke Resistance to endocrine therapy: are breast cancer stem cells the culprits J Mammary Gland Biol Neoplasia 14 2009 45 54
25. H. Korkaya, A. Paulson, F. Iovino, and M.S. Wicha HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 27 2008 6120 6130
26. F. Reim, Y. Dombrowski, and C. Ritter Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44 high/CD24 low/Her2low breast cancer stem cells Cancer Res 69 2009 8058 8066
27. R. Nahta, D. Yu, and M.C. Hung Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 2006 269 280 (Pubitemid 43731112)
28. P.L. Bedard, E. de Azambuja, and F. Cardoso Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer Curr Cancer Drug Targets 9 2009 148 162
29. F. Reim, Y. Dombrowski, and C. Ritter Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells Cancer Res 69 2009 8058 8066
30. K.B. Horwitz The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk Mol Endocrinol 22 2008 2743 2750
31. E. Mylona, I. Giannopoulou, and E. Fasomytakis The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas Hum Pathol 39 2008 1096 1102
32. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis Clin Cancer Res 11 2005 11549
33. M. Kakarala, and M.S. Wicha Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy J Clin Oncol 26 2008 2813 2820
34. F. Yu, H. Yao, and P. Zhu Let-7 regulates self renewal and tumorigenicity of breast cancer cells Cell 131 2007 1109 1123 (Pubitemid 350235025)
35. T.M. Phillips, W.H. McBride, and F. Pajonk The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation J Natl Cancer Ins 98 2006 1777 1785 (Pubitemid 46017929)
36. B. Keam, S.A. Im, and M. Gauthier Ki-67 can be used for further classification of triple negative breast cancer into 2 subtypes with different response and prognosis Breast Cancer Res 13 2011 R22
37. C.T. Brekelmans, M.M. Tilanus-Linthorst, and C. Seynaeve Tumor characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and BRCA1/2 families as compared to sporadic breast cancer cases Eur J Cancer 43 2007 867 876 (Pubitemid 46366688)
38. X. Li, M.T. Lewis, and J. Huang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 2008 672 679
39. J.M. Reuben, B.N. Lee, and H. Gao Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype Eur J Cancer 47 2011 1527 1536
40. A.M. Calcagno, C.D. Salcido, and J.P. Gillet Prolonged drug selection of breast cancer stem cells and enrichment of cancer stem cell characteristics J Natl Cancer Inst 102 2010 1637 1652
41. K. Subik, J.F. Lee, and L. Baxter The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67, and AR by immunohistochemical analysis in breast cancer cell lines Breast Cancer (Auckl) 4 2010 34 41